0.02 | 0.55%
| Price and Volume | |
|---|---|
| Recent Price | 3.66 |
| 52 Week High | 3.74 |
| 52 Week Low | 1.52 |
| Avg. Daily Vol. (Mil) | 0.10 |
| Beta (3 year) | 2.39 |
| Share Related Items | |
| Mkt Cap (Mil) | 142.88 |
| Shares Out (Mil) | 39.04 |
| Float (Mil) | 21.58 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 4.40 |
| Current Ratio | 4.80 |
| LT Debt/ Equity | 0.30 |
| Total Debt / Equity | 0.31 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 1.16K |
| Price/Book | 9.44 |
| Price/Cash Flow | -5.50 |
| Per Share Data | |
| Earnings | -0.83 |
| Sales | 0.00 |
| Book Value | 0.39 |
| Cash Flow | -0.67 |
| Business Summary | |
|---|---|
| A development stage medical device company focused on the design and development of devices that use neuroblocking technology to treat obesity, its associated co-morbidities, and other gastrointestinal disorders. | |
| General Information | |
| 2800 Patton Road
St. Paul, MN 55113 |
|
| www.enteromedics.com | |
| Industry : Health Services | |
| Sector: Health Care | |
| Employees: 33 | |
| CEO: Mark B. Knudson,PhD | |
| Short Interest | |
| Current Month (Mil) | 0.07 |
| Previous Month (Mil) | 0.08 |
| Short Interest Ratio (Days) | 0.60 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -108.10 |
| Return on Investments | -135.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,580.69 | 1,332.42 | 2,870.99 | 17.31 |
Oil *
106.79
|
|
UP
125.86 |
UP
14.60 |
UP
33.46 |
DOWN
0.14 |
10 Yr
1.73%
SPDR Gold
151.02
|
|
+1.01%
|
+1.11%
|
+1.18%
|
-0.80%
|
Data delayed 20 minutes |
Connect with TheStreet